142 related articles for article (PubMed ID: 33049741)
21. Genetics of gigantism and acromegaly.
Hannah-Shmouni F; Trivellin G; Stratakis CA
Growth Horm IGF Res; 2016; 30-31():37-41. PubMed ID: 27657986
[TBL] [Abstract][Full Text] [Related]
22. Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome.
Naves LA; Daly AF; Dias LA; Yuan B; Zakir JC; Barra GB; Palmeira L; Villa C; Trivellin G; Júnior AJ; Neto FF; Liu P; Pellegata NS; Stratakis CA; Lupski JR; Beckers A
Endocrine; 2016 Feb; 51(2):236-44. PubMed ID: 26607152
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients.
Gsponer J; De Tribolet N; Déruaz JP; Janzer R; Uské A; Mirimanoff RO; Reymond MJ; Rey F; Temler E; Gaillard RC; Gomez F
Medicine (Baltimore); 1999 Jul; 78(4):236-69. PubMed ID: 10424206
[TBL] [Abstract][Full Text] [Related]
24. Acromegaly.
Scacchi M; Cavagnini F
Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
[TBL] [Abstract][Full Text] [Related]
25. Congenital hypopituitarism in two brothers with a duplication of the 'acrogigantism gene' GPR101: clinical findings and review of the literature.
Elizabeth MSM; Verkerk AJMH; Hokken-Koelega ACS; Verlouw JAM; Argente J; Pfaeffle R; Neggers SJCMM; Visser JA; de Graaff LCG
Pituitary; 2021 Apr; 24(2):229-241. PubMed ID: 33184694
[TBL] [Abstract][Full Text] [Related]
26. Effective Long-term Pediatric Pegvisomant Monotherapy to Final Height in X-linked Acrogigantism.
Burren CP; Williams G; Coxson E; Korbonits M
JCEM Case Rep; 2023 May; 1(3):luad028. PubMed ID: 37908565
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N
J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
[TBL] [Abstract][Full Text] [Related]
28. Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly.
Arihara Z; Sakurai K; Yamashita R; Niitsuma S; Ueno T; Yamamura N; Yamada S; Inoshita N; Takahashi K
Tohoku J Exp Med; 2014 Oct; 234(2):129-35. PubMed ID: 25253414
[TBL] [Abstract][Full Text] [Related]
29. The characteristics of acromegalic patients with hyperprolactinemia and the differences in patients with merely GH-secreting adenomas: clinical analysis of 279 cases.
Wang M; Mou C; Jiang M; Han L; Fan S; Huan C; Qu X; Han T; Qu Y; Xu G
Eur J Endocrinol; 2012 May; 166(5):797-802. PubMed ID: 22334636
[TBL] [Abstract][Full Text] [Related]
30. Changing patterns of insulin-like growth factor-I and glucose-suppressed growth hormone levels after pituitary surgery in patients with acromegaly.
Espinosa-de-los-Monteros AL; Mercado M; Sosa E; Lizama O; Guinto G; Lopez-Felix B; Garcia O; Hernández I; Ovalle A; Mendoza V
J Neurosurg; 2002 Aug; 97(2):287-92. PubMed ID: 12186455
[TBL] [Abstract][Full Text] [Related]
31. Neurofibromatosis Type 1 Has a Wide Spectrum of Growth Hormone Excess.
Hannah-Shmouni F; Trivellin G; Beckers P; Karaviti LP; Lodish M; Tatsi C; Adesina AM; Adamidou F; Mintziori G; Josefson JL; Quezado M; Stratakis CA
J Clin Med; 2022 Apr; 11(8):. PubMed ID: 35456261
[TBL] [Abstract][Full Text] [Related]
32. Case of Acromegaly Caused by Rathke Cleft Cyst Mimicking Plurihormonal Pituitary Adenoma.
Morinaga Y; Nii K; Sakamoto K; Inoue R; Mitsutake T; Hanada H
World Neurosurg; 2019 Jun; 126():570-575. PubMed ID: 30862574
[TBL] [Abstract][Full Text] [Related]
33. Type 1 diabetes associated with asymptomatic acromegaly successfully treated with surgery after pregnancy: a case report.
Iwai H; Ito H; Ri S; Harada T; Hirota N; Yamauchi T; Miyatake T; Ohno Y; Aoki N
Endocr J; 2005 Aug; 52(4):413-20. PubMed ID: 16127208
[TBL] [Abstract][Full Text] [Related]
34. Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria.
Hazer DB; Işık S; Berker D; Güler S; Gürlek A; Yücel T; Berker M
J Neurosurg; 2013 Dec; 119(6):1467-77. PubMed ID: 24074496
[TBL] [Abstract][Full Text] [Related]
35. Diagnosis and treatment of pituitary adenomas.
Chanson P; Salenave S
Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
[TBL] [Abstract][Full Text] [Related]
36. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
37. Presurgical octreotide treatment in acromegaly: no improvement of final growth hormone (GH) concentration and pituitary function. A long-term case-control study.
Plöckinger U; Quabbe HJ
Acta Neurochir (Wien); 2005 May; 147(5):485-93; discussion 493. PubMed ID: 15806331
[TBL] [Abstract][Full Text] [Related]
38. 'Silent' somatotropinoma.
Pawlikowski M; Kuta J; Fuss-Chmielewska J; Winczyk K
Endokrynol Pol; 2012; 63(2):88-91. PubMed ID: 22538745
[TBL] [Abstract][Full Text] [Related]
39. ACTH response to desmopressin in a patient with acromegaly; expression of corticotropin-releasing factor, urocortins and vasopressin V1b receptor in GH-producing pituitary adenoma.
Arihara Z; Sakurai K; Osaki Y; Fukazawa H; Yamada S; Inoshita N; Murakami O; Ohba K; Takahashi K
Endocr J; 2011; 58(12):1029-36. PubMed ID: 21908929
[TBL] [Abstract][Full Text] [Related]
40. Low insulin resistance after surgery predicts poor GH suppression one year after complete resection for acromegaly: a retrospective study.
Edo N; Morita K; Suzuki H; Takeshita A; Miyakawa M; Fukuhara N; Nishioka H; Yamada S; Takeuchi Y
Endocr J; 2016 May; 63(5):469-77. PubMed ID: 26949262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
